An open-label phase II study of intermittent oral capecitabine (X) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC)

3730 Background: X is an orally administered, fluoropyrimidine carbamate that is converted to 5-FU in tumors by the enzyme thymidine phosphorylase (TP). The localization of TP within tumors results...